PCV49 COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS

Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1375470 ◽

2017 ◽

Vol 34 (1) ◽

pp. 55-63 ◽

Cited By ~ 3

Author(s):

Siyang Peng ◽

Kristen A. Deger ◽

Anastasia Ustyugova ◽

Pranav Gandhi ◽

Nan Qiao ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Real World ◽

Stroke Prevention ◽

Medicare Beneficiaries ◽

Effectiveness Analysis ◽

Real World Evidence

Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding

PharmacoEconomics ◽

10.1007/s40273-018-0741-3 ◽

2018 ◽

Vol 37 (2) ◽

pp. 279-289 ◽

Cited By ~ 4

Author(s):

Thananan Rattanachotphanit ◽

Chulaporn Limwattananon ◽

Onanong Waleekhachonloet ◽

Phumtham Limwattananon ◽

Kittisak Sawanyawisuth

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

High Risk ◽

Stroke Prevention ◽

Oral Anticoagulants ◽

Risk Of Bleeding ◽

Effectiveness Analysis ◽

Direct Acting ◽

Direct Acting Oral Anticoagulants

PCV54 Cost-Effectiveness Analysis of Dabigatran Compared to Warfarin for Stroke Prevention in Atrial Fibrillation in a Medicare Population

Value in Health ◽

10.1016/j.jval.2012.03.657 ◽

2012 ◽

Vol 15 (4) ◽

pp. A121

Author(s):

M.A. Ward ◽

A.K. Biddle

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Medicare Population ◽

PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

Value in Health ◽

10.1016/j.jval.2011.02.237 ◽

2011 ◽

Vol 14 (3) ◽

pp. A41

Author(s):

Y. Zhao ◽

L. Lim ◽

C.I. Coleman

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Effectiveness Analysis ◽

Dose Warfarin ◽

Adjusted Dose

PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS

Value in Health ◽

10.1016/j.jval.2018.09.630 ◽

2018 ◽

Vol 21 ◽

pp. S106

Author(s):

F. de Andrés-Nogales ◽

I. Oyagüez ◽

C. Suarez ◽

J.L. Lopez-Sendon ◽

J.R. Gonzalez-Juanatey ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation

BMC Cardiovascular Disorders ◽

10.1186/s12872-016-0351-y ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 3

Author(s):

Vivian Wing-Yan Lee ◽

Ronald Bing-Ching Tsai ◽

Ines Hang-Iao Chow ◽

Bryan Ping-Yen Yan ◽

Mehmet Gungor Kaya ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Left Atrial ◽

Left Atrial Appendage ◽

Atrial Appendage ◽

Left Atrial Appendage Occlusion ◽

Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation (SPAF) in the Indonesian healthcare setting

INDONESIAN JOURNAL OF PHARMACY ◽

10.14499/indonesianjpharm30iss1pp74 ◽

2019 ◽

Vol 30 (1) ◽

pp. 74

Author(s):

Iwan Dwiprahasto ◽

Erna Kristin ◽

Dwi Endarti ◽

Rizaldy Taslim Pinzon ◽

Alfi Yasmina ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Healthcare Setting ◽

Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

Clinical Drug Investigation ◽

10.1007/s40261-013-0144-3 ◽

2013 ◽

Vol 34 (1) ◽

pp. 9-17 ◽

Cited By ~ 35

Author(s):

Carla Rognoni ◽

Monia Marchetti ◽

Silvana Quaglini ◽

Nicola Lucio Liberato

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

WITHDRAWN: Cost-effectiveness analysis of left atrial appendage occlusion compared with seven pharmacological strategies for stroke prevention in atrial fibrillation

Clinical Trials and Regulatory Science in Cardiology ◽

10.1016/j.ctrsc.2015.08.005 ◽

2015 ◽

Author(s):

Vivian Wing-Yan Lee ◽

Ronald Bing-Ching Tsai ◽

Ines Hang-Iao Chow ◽

Bryan Ping-Yen Yan ◽

Mehmet Gungor Kaya ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Left Atrial ◽

Left Atrial Appendage ◽

Atrial Appendage ◽

Left Atrial Appendage Occlusion ◽

PCV77 Economic Evaluation of Dabigatran Etexilate 150dib for the Stroke Prevention in Atrial Fibrillation in Greece: A Cost –Effectiveness Analysis under the Greek NHS Setting

Value in Health ◽

10.1016/j.jval.2011.08.797 ◽

2011 ◽

Vol 14 (7) ◽

pp. A378

Author(s):

V. Fragoulakis ◽

T. Theodoratou ◽

N. Maniadakis

Keyword(s):

Atrial Fibrillation ◽

Economic Evaluation ◽

Cost Effectiveness ◽

Stroke Prevention ◽

Dabigatran Etexilate ◽